As compared with placebo, early administration of abciximab in patients with acute myocardial infarction improves coronary patency before stenting, the success rate of the stenting procedure, the rate of coronary patency at six months, left ventricular function, and clinical outcomes.

The FRANCE TAVI registry provided reassuring data regarding trends in TAVR performance in an all-comers population on a national scale. Nonetheless, given that TAVR indications are likely to expand to patients at lower surgical risk, concerns remain regarding potentially life-threatening complications and pacemaker implantation. (Registry of Aortic Valve Bioprostheses Established by Catheter [FRANCE TAVI]; NCT01777828).

HE OPTIMAL INTERVENTION IN the treatment strategy of patients presenting with acute coronary syndromes without ST-segment elevation (NSTE-ACS) has been debated for years. Numerous studies, randomized trials, and metaanalyses have investigated the potential benefits of invasive over conservative strategies, and most have suggested a prolonged advantage of an invasive approach for the prevention of death or myocardial infarction (MI), particularly among high-risk patients. 1-14 If an invasive strategy is generally accepted to be the best option and is currently recommended in high-risk patients, little information is available regarding the optimal timing of coronary angiography and intervention. 15,16 Only 2 randomized studies evaluated the timing of intervention (early vs late) with patients in the 2 study groups receiv-Author Affiliations are listed at the end of this article.

Periprocedural MI and injury are frequent complications of elective PCI associated with an increased rate of cardiovascular events at 30 days and 1 year.